About this Research Topic
Ferroptosis is a form of regulated cell death characterized by the iron-dependent accumulation of lipid peroxides, leading to a cascade of oxidative damage and cell membrane rupture. Unlike apoptosis or necrosis, ferroptosis has distinct morphological and biochemical features, making it a unique mode of programmed cell death. The tumor immune microenvironment (TIME) represents a dynamic ecosystem wherein cancer cells engage in intricate crosstalk with immune cells, stromal components, and various soluble factors. Within this milieu, ferroptosis has garnered attention for its potential dual role—both as a driver of tumorigenesis and as a modulator of immune responses.
Recent evidence suggests that the intricate interplay between these pathways within the tumor immune microenvironment contributes to a pro-tumorigenic milieu. Conversely, the immunomodulatory effects of ferroptotic cell death may hold the key to enhancing antitumor immune responses. Unraveling the delicate balance between ferroptosis induction and suppression in the TIME presents a unique opportunity to dissect the molecular intricacies governing cancer biology.
This research topic aims to delve into the multifaceted roles of ferroptosis within the tumor immune microenvironment, with a specific focus on its regulation mechanisms, impact on tumor progression, and implications for therapeutic interventions. By exploring the intricate connections between ferroptosis and immune responses, we seek to unravel novel avenues for precision medicine and therapeutic exploitation.
Potential topics include, but are not limited to, the following:
1. Tumor Immunology: Investigating the complex role of ferroptosis between cancer cells and immune cells within the TME, including mechanisms of immune evasion and resistance.
2. Programmed Cell Death Mechanisms: Delving into the molecular pathways and signaling cascades that regulate ferroptosis in the TME related to cancer immunotherapy.
3. Immunotherapy: Exploring novel immunotherapeutic approaches, such as immune checkpoint inhibitors, CAR-T cell therapies, and therapeutic vaccines, and their synergistic effects with cell ferroptosis inducers.
4. Stromal Cells and TME Modulation: Understanding the role of stromal cells (e.g., cancer-associated fibroblasts, endothelial cells) and extracellular matrix components in shaping the TME and influencing cell ferroptosis mechanisms.
5. Cancer Metabolism: Investigating metabolic reprogramming in cancer cells and its impact on cell ferroptosis pathways, including the role of nutrient availability, hypoxia, and metabolic stress.
6. Clinical Translational Research: Conducting clinical trials to evaluate the efficacy, safety, and biomarker correlates of novel therapeutic strategies targeting cell ferroptosis mechanisms in cancer patients, including patient stratification and personalized medicine approaches.
*NOTE: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation are considered out of the scope of this Research Topic.
Recent evidence suggests that the intricate interplay between these pathways within the tumor immune microenvironment contributes to a pro-tumorigenic milieu. Conversely, the immunomodulatory effects of ferroptotic cell death may hold the key to enhancing antitumor immune responses. Unraveling the delicate balance between ferroptosis induction and suppression in the TIME presents a unique opportunity to dissect the molecular intricacies governing cancer biology.
This research topic aims to delve into the multifaceted roles of ferroptosis within the tumor immune microenvironment, with a specific focus on its regulation mechanisms, impact on tumor progression, and implications for therapeutic interventions. By exploring the intricate connections between ferroptosis and immune responses, we seek to unravel novel avenues for precision medicine and therapeutic exploitation.
Potential topics include, but are not limited to, the following:
1. Tumor Immunology: Investigating the complex role of ferroptosis between cancer cells and immune cells within the TME, including mechanisms of immune evasion and resistance.
2. Programmed Cell Death Mechanisms: Delving into the molecular pathways and signaling cascades that regulate ferroptosis in the TME related to cancer immunotherapy.
3. Immunotherapy: Exploring novel immunotherapeutic approaches, such as immune checkpoint inhibitors, CAR-T cell therapies, and therapeutic vaccines, and their synergistic effects with cell ferroptosis inducers.
4. Stromal Cells and TME Modulation: Understanding the role of stromal cells (e.g., cancer-associated fibroblasts, endothelial cells) and extracellular matrix components in shaping the TME and influencing cell ferroptosis mechanisms.
5. Cancer Metabolism: Investigating metabolic reprogramming in cancer cells and its impact on cell ferroptosis pathways, including the role of nutrient availability, hypoxia, and metabolic stress.
6. Clinical Translational Research: Conducting clinical trials to evaluate the efficacy, safety, and biomarker correlates of novel therapeutic strategies targeting cell ferroptosis mechanisms in cancer patients, including patient stratification and personalized medicine approaches.
*NOTE: Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation are considered out of the scope of this Research Topic.
Keywords: Ferroptosis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
